Familial adenomatous polyposis
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients who visited Hyogo Medical University Hospital or participating institutions between January 1, 2016 and December 31, 2023, were clinically diagnosed with familial adenomatous polyposis (FAP), and were found to have duodenal adenomas or duodenal carcinoma on esophagogastroduodenoscopy during the observation period.
Exclusion criteria
Exclusion criteria: (a) Fewer than two EGDs during observation (b) Prior surgeries preventing duodenal observation (gastrectomy, pancreaticoduodenectomy, etc.) (c) Current or past chemotherapy for non-duodenal malignancies (d) Inflammatory bowel disease (e) Opt-out request from the participant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in time until progression of Spigelman stage between patients at IDP group and those at non-IDP group. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of duodenal cancer and duodenal surgery in IDP vs. non-IDP groups Proportion of patients with stage IV Spigelman classification at 2 years after endoscopic treatment and at the final EGD Comparison of longitudinal Spigelman stage changes between IDP and non-IDP groups These secondary outcomes will be evaluated in a comprehensive and exploratory manner. | — |
Countries
Japan
Contacts
Hyogo Medical University School of Medicine Department of Gastroenterology